Double-Blinded Randomized Controlled Study Investigating the Efficacy of Exparel (Liposomal Bupivacaine) for Postoperative Pain Relief in Mandibular Third Molar Extractions

• Status: Not yet recruiting
• Trial end date: 2023-03-01
• Target enrollment: 0
• Participant gender: All

Summary

The most prevalent complaint after third molar extractions is pain. There have been many modalities and regimens developed to manage post-operative pain, such as modifications in surgical techniques, locally-applied medicaments, and oral analgesics. Recently, liposomal bupivacaine (Exparel) has been FDA approved for single-dose infiltration in the oral cavity in adults and children (6 years or older) to produce extended postsurgical local anesthesia. We hypothesize that the administration of liposomal bupivacaine (Exparel) at the end of third molar extractions will decrease postoperative pain and decrease narcotic use for pain management.

• Phase: Phase 4
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: University of Southern California
• Treatments: Bupivacaine; Epinephrine

Criteria

Inclusion Criteria:

All patients receiving bilateral mandibular third molar extractions at the Herman Ostrow School of Dentistry by an oral & maxillofacial surgery resident will be candidates for the study.

Exclusion Criteria:

Patient unable to complete form for four days postoperatively. Patient with severe hepatic disease, history of allergy or contraindication to amide-type LA or opioids, recent history of antibiotic use within the past thirty days. Patients with use of long-acting opioids, NSAIDs, aspirin, acetaminophen within 3 days prior to screening. Patients who are pregnant. Patients receiving additional mandibular teeth extractions.